In The News: School of Integrated Health Sciences

BioSpace

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Health Market

Diabetes turns out to be one of the factors in the development of Alzheimer's disease. One of the main features of diabetes - hyperglycemia - is responsible for alzheimer's-like changes.

DOCTOR PETER

A study by neuroscientists at the University of Nevada Las Vegas (UNLV) showed that chronic hyperglycemia also impairs memory.

Trial Site News

Ê×Ò³| Â鶹´«Ã½Ó³»­ (UNLV) neuroscientists report on study findings purportedly strengthening the link between Type 2 diabetes and Alzheimer’s disease.

KNPR News

UNLV just held a class in the school of hard knocks.

Technology Networks

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

MegaDoctor News

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer’s disease.

News Medical

A team of UNLV neuroscientists has strengthened the link between Type II diabetes and Alzheimer's disease.

Todo Noticias

Neuroscientists show that chronic hyperglycemia affects fundamental aspects of memory.

Knowridge Science Report

In a new study from the Ê×Ò³| Â鶹´«Ã½Ó³»­, researchers confirmed the link between type 2 diabetes and Alzheimer’s disease.

Pharmabiz

Eisai and Biogen announced that Eisai has initiated a rolling submission to the US Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab (BAN2401), the company’s investigational anti-amyloid beta (Aß) protofibril antibody, for the treatment of early Alzheimer’s disease (early AD).

Being Patient

Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.